Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.

Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Harrod ME, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group.

J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]

PMID:
31698545
2.

An Original Description of Granulomatous Liver Cirrhosis in Blau Syndrome.

Cropley A, Ashrafy AH, Weltman M.

Dig Dis Sci. 2019 Nov;64(11):3346-3349. doi: 10.1007/s10620-019-05682-8. Epub 2019 Jun 1. No abstract available.

PMID:
31154542
3.

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.

Nicoll AJ, Roberts SK, Lim R, Mitchell J, Weltman M, George J, Wigg A, Stuart K, Gow P, MacQuillan G, Tse E, Levy M, Sood S, Zekry A, Cheng W, Mitchell J, Skoien R, Sievert W, Strasser SI, McCaughan GW; ALA Clinical Research Network, Gastroenterological Society of Australia.

Aliment Pharmacol Ther. 2019 May;49(10):1314-1322. doi: 10.1111/apt.15248. Epub 2019 Apr 11.

PMID:
30972807
4.

A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms.

Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D, Dore GJ, Spengler U, Lampertico P, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Santoro R, Gallego-Durán R, Fischer J, Nattermann J, D'Ambrosio R, McLeod D, Powell E, Latchoumanin O, Thabet K, Najim MAM, Douglas MW, Liddle C, Qiao L, George J, Eslam M; International Liver Disease Genetics Consortium (ILDGC).

Sci Rep. 2019 Feb 5;9(1):1439. doi: 10.1038/s41598-018-35736-2.

5.

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.

Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group.

Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22.

PMID:
30352330
6.

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM.

Hepatol Commun. 2018 Aug 30;2(9):1037-1050. doi: 10.1002/hep4.1209. eCollection 2018 Sep.

7.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.

PMID:
29310928
8.

Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.

Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):268-277. doi: 10.1016/j.cgh.2017.09.063. Epub 2017 Oct 16.

PMID:
29050991
9.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19.

PMID:
28633998
10.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16.

PMID:
28624134
11.

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group.

BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

12.

Esophageal squamous papilloma lacks clear clinicopathological associations.

Jideh B, Weltman M, Wu Y, Chan CHY.

World J Clin Cases. 2017 Apr 16;5(4):134-139. doi: 10.12998/wjcc.v5.i4.134.

13.

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.

Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN).

Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168.

PMID:
28422043
14.

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Douglas MW, Liddle C, Powell E, Romero-Gomez M, George J; International Liver Disease Genetics Consortium (ILDGC).

Nat Genet. 2017 May;49(5):795-800. doi: 10.1038/ng.3836. Epub 2017 Apr 10.

PMID:
28394349
15.

The use of immunosuppression in autoimmune hepatitis: A current literature review.

Cropley A, Weltman M.

Clin Mol Hepatol. 2017 Mar;23(1):22-26. doi: 10.3350/cmh.2016.0089. Epub 2017 Mar 14. Review.

16.

Lymphocytic esophagitis: Report of three cases and review of the literature.

Jideh B, Keegan A, Weltman M.

World J Clin Cases. 2016 Dec 16;4(12):413-418. doi: 10.12998/wjcc.v4.i12.413.

17.

Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.

Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H.

Hepatol Int. 2016 Nov;10(6):909-915. Epub 2016 Sep 20. Review.

PMID:
27649967
18.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium.

Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757.

19.

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.

O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR.

Genes Immun. 2016 Sep;17(6):328-34. doi: 10.1038/gene.2016.27. Epub 2016 Jun 16.

20.

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.

Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J; International Liver Disease Genetics Consortium.

Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.

21.

FibroGENE: A gene-based model for staging liver fibrosis.

Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlenstiel G, McLeod D, Powell E, Liddle C, Douglas MW, Booth DR, George J; International Liver Disease Genetics Consortium (ILDGC).

J Hepatol. 2016 Feb;64(2):390-398. doi: 10.1016/j.jhep.2015.11.008. Epub 2015 Dec 1.

22.

Metastatic periampullary clear cell renal carcinoma.

Jideh B, Chen H, Weltman M, Chan CH.

Gastrointest Endosc. 2016 May;83(5):1040-2; discussion 1042. doi: 10.1016/j.gie.2015.10.048. Epub 2015 Nov 7. No abstract available.

PMID:
26555298
23.

Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.

Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; ETHOS Study Group.

Addiction. 2016 Feb;111(2):311-9. doi: 10.1111/add.13197. Epub 2015 Nov 25.

PMID:
26451534
24.

Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia.

Koloski NA, Jones M, Weltman M, Kalantar J, Bone C, Gowryshankar A, Walker MM, Talley NJ.

Neurogastroenterol Motil. 2015 Sep;27(9):1317-25. doi: 10.1111/nmo.12626. Epub 2015 Jul 22.

PMID:
26202154
25.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC).

Nat Commun. 2015 Mar 5;6:6422. doi: 10.1038/ncomms7422.

26.

Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.

Fragomeli V, Weltman M.

J Gastroenterol Hepatol. 2015 Mar;30 Suppl 2:6-11. doi: 10.1111/jgh.12864.

PMID:
25641224
27.

Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection.

Kitson MT, George J, Dore GJ, Leung R, Button P, McCaughan GW, Grawford DH, Siebert W, Weltman MD, Cheng WS, Roberts SK.

J Gastroenterol Hepatol. 2014;29(7):1458-62.

PMID:
25587616
28.

Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis.

Kemp W, Levy M, Weltman M, Lubel J; Australian Liver Association (ALA).

J Gastroenterol Hepatol. 2015 Mar;30(3):453-62. doi: 10.1111/jgh.12865. Review.

PMID:
25532416
29.

Education and Imaging. Gastrointestinal: pyoderma gangrenosum of the thumb.

Sundaralingam P, Weltman M.

J Gastroenterol Hepatol. 2014 Sep;29(9):1659. doi: 10.1111/jgh.12678. No abstract available.

PMID:
25154441
30.

An uncommon complication of percutaneous endoscopic gastrostomy tube placement.

Chan CH, Weltman MD, Adams S.

Gastroenterology. 2014 Aug;147(2):e3-4. doi: 10.1053/j.gastro.2014.02.041. Epub 2014 Jun 25. No abstract available.

PMID:
24973687
31.

Multifocal peliosis hepatis simulating metastatic malignancy.

Liu C, Pasupathy A, Weltman M.

Dig Liver Dis. 2014 Sep;46(9):862-3. doi: 10.1016/j.dld.2014.04.015. Epub 2014 Jun 2. No abstract available.

PMID:
24890622
32.

Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots.

Milner KL, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, Xu A, George J, Chisholm DJ.

J Viral Hepat. 2014 May;21(5):325-32. doi: 10.1111/jvh.12143. Epub 2013 Aug 12.

PMID:
24716635
33.

ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.

Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, Visvanathan K, Sundararajan V, Desmond PV, Bowden DS, Matthews GV, Thompson AJ; CHARIOT Study Group.

Hepatology. 2014 Jun;59(6):2152-60. doi: 10.1002/hep.27022. Epub 2014 Apr 25.

PMID:
24449403
34.

Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.

Gibson PR, Vaizey C, Black CM, Nicholls R, Weston AR, Bampton P, Sparrow M, Lawrance IC, Selby WS, Andrews JM, Walsh AJ, Hetzel DJ, Macrae FA, Moore GT, Weltman MD, Leong RW, Fan T.

J Crohns Colitis. 2014 Jul;8(7):598-606. doi: 10.1016/j.crohns.2013.11.017. Epub 2013 Dec 15.

PMID:
24345767
35.

Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort.

Walker MM, Aggarwal KR, Shim LS, Bassan M, Kalantar JS, Weltman MD, Jones M, Powell N, Talley NJ.

J Gastroenterol Hepatol. 2014 Mar;29(3):474-9. doi: 10.1111/jgh.12419.

PMID:
24304041
36.

Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly.

Chen J, Eslick GD, Weltman M.

Aliment Pharmacol Ther. 2014 Jan;39(2):117-24. doi: 10.1111/apt.12563. Epub 2013 Nov 22. Review.

37.

Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.

Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network.

J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424.

PMID:
24219707
38.

IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.

O'Connor KS, Ahlenstiel G, Suppiah V, Schibeci S, Ong A, Leung R, van der Poorten D, Douglas MW, Weltman MD, Stewart GJ, Liddle C, George J, Booth DR.

Innate Immun. 2014 Aug;20(6):598-605. doi: 10.1177/1753425913503385. Epub 2013 Sep 17.

PMID:
24045339
39.

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES.

Gastroenterology. 2013 Oct;145(4):790-800.e3. doi: 10.1053/j.gastro.2013.06.051. Epub 2013 Jun 26.

PMID:
23811112
40.

Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, Radford-Smith G, Selby W, Veillard AS, Grimm MC, Travis SP, Lawrance IC.

J Crohns Colitis. 2013 Nov;7(10):e449-56. doi: 10.1016/j.crohns.2013.02.019. Epub 2013 Apr 17.

PMID:
23601754
41.

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection.

Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC).

Genes Immun. 2013 Jul-Aug;14(5):286-90. doi: 10.1038/gene.2013.15. Epub 2013 Apr 18.

42.

Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways.

Skoien R, Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, O'Brien PE, Tilg H, Moschen AR, Baumann U, Brown RM, Couper RT, Manton ND, Ee LC, Weltman M, Clouston AD.

Liver Int. 2013 Apr;33(4):624-32. doi: 10.1111/liv.12100. Epub 2013 Jan 29.

PMID:
23356584
43.

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.

Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, Sievert W, Weltman MD, Cheng WS, Roberts SK.

J Hepatol. 2013 Mar;58(3):467-72. doi: 10.1016/j.jhep.2012.11.017. Epub 2012 Nov 23.

PMID:
23183524
44.

Psychological impact and risk factors associated with new onset fecal incontinence.

Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ.

J Psychosom Res. 2012 Dec;73(6):464-8. doi: 10.1016/j.jpsychores.2012.07.013. Epub 2012 Aug 19.

PMID:
23148816
45.

Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.

Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M.

Expert Opin Drug Saf. 2012 Nov;11(6):901-9. doi: 10.1517/14740338.2012.721927. Epub 2012 Sep 4.

PMID:
22943161
46.

Hepatitis C treatment outcomes in Australian clinics.

Gidding HF, Law MG, Amin J, Ostapowicz G, Weltman M, Macdonald GA, Sasadeusz JJ, Haber PA, George J, Dore GJ.

Med J Aust. 2012 Jun 4;196(10):633-7.

PMID:
22676878
47.

Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients.

Crawford DH, Dore GJ, Sievert W, Cheng WS, Weltman M, McCaughan G, Rawlinson W, Marks PS, Yoshihara M, Rizkalla B, Roberts SK; CHARIOT Study Group.

Antivir Ther. 2012;17(5):849-54. doi: 10.3851/IMP2104. Epub 2012 Apr 18.

PMID:
22513456
48.

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.

Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ.

Gut. 2012 Sep;61(9):1284-90. doi: 10.1136/gutjnl-2011-300474. Epub 2012 Jan 10.

PMID:
22234979
49.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC).

PLoS Med. 2011 Sep;8(9):e1001092. doi: 10.1371/journal.pmed.1001092. Epub 2011 Sep 13.

50.

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort.

Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC).

Genome Med. 2011 Aug 31;3(8):57. doi: 10.1186/gm273.

Supplemental Content

Loading ...
Support Center